TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice

Molecular Metabolism

Volumn 4, Issue 10, 2015, Pages 741-752

  Stöhr, Robert ^a,b   Kappel, Ben Arpad ^a,b   Carnevale, Daniela ^c,d   Cavalera, Michele ^a   Mavilio, Maria ^a   Arisi, Ivan ^e   Fardella, Valentina ^c   Cifelli, Giuseppe ^c   Casagrande, Viviana ^a   Rizza, Stefano ^a   Cattaneo, Antonino ^e,f   Mauriello, Alessandro ^a   Menghini, Rossella ^a   Lembo, Giuseppe ^c   Federici, Massimo ^a,g  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c IRCCS NEUROMED   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^f SCUOLA NORMALE SUPERIORE   (Italy)

^g TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Apelin; Arrhythmia; Heart; Lipid metabolism; Oxidative stress; TIMP3

Indexed keywords

APELIN; APOLIPOPROTEIN E; FATTY ACID; LIPID; LONG CHAIN FATTY ACID; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; ELECTROCARDIOGRAM; ENERGY METABOLISM; FATTY ACID OXIDATION; HEART FUNCTION; HEART INFARCTION; HEART STRESS; HISTOLOGY; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPID DIET; LIPID METABOLISM; LIPID OXIDATION; METABOLIC STRESS; METABOLOMICS; MORTALITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; STRESS; TELEMETRY; WESTERN BLOTTING;

EID: 84942196499     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2015.07.007     Document Type: Article

References (63)

1. Lopaschuk G.D., Ussher J.R., Folmes C.D., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiological Reviews 2010, 90:207-258.
2. Schafer Z.T., Grassian A.R., Song L., Jiang Z., Gerhart-Hines Z., Irie H.Y., et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009, 461:109-113.
3. Spinale F.G., Zile M.R. Integrating the myocardial matrix into heart failure recognition and management. Circulation Research 2013, 113:725-738.
4. Carnevale D., Lembo G. Placental growth factor and cardiac inflammation. Trends in Cardiovascular Medicine 2012, 22:209-212.
5. Federici M., Hribal M.L., Menghini R., Kanno H., Marchetti V., Porzio O., et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. Journal of Clinical Investigation 2005, 115:3494-3505.
6. Cardellini M., Menghini R., Martelli E., Casagrande V., Marino A., Rizza S., et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 2009, 58:2396-2401.
7. Menghini R., Casagrande V., Menini S., Marino A., Marzano V., Hribal M.L., et al. TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes 2012, 61:454-462.
8. Menghini R., Menini S., Amoruso R., Fiorentino L., Casagrande V., Marzano V., et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 2009, 136:663-672.
9. Fiorentino L., Cavalera M., Menini S., Marchetti V., Mavilio M., Fabrizi M., et al. Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay. EMBO Molecular Medicine 2013, 5:441-455.
10. Casagrande V., Menghini R., Menini S., Marino A., Marchetti V., Cavalera M., et al. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arteriosclerosis Thrombosis and Vascular Biology 2012, 32:74-81.
11. Monroy A., Kamath S., Chavez A.O., Centonze V.E., Veerasamy M., Barrentine A., et al. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 2009, 52:2169-2181.
12. Khokha R., Murthy A., Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nature Reviews Immunology 2013, 13:649-665.
13. Basu R., Lee J., Morton J.S., Takawale A., Fan D., Kandalam V., et al. TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension. Cardiovascular Research 2013, 98:360-371.
14. Basu R., Fan D., Kandalam V., Lee J., Das S.K., Wang X., et al. Loss of Timp3 gene leads to abdominal aortic aneurysm formation in response to angiotensin II. Journal of Biological Chemistry 2012, 287:44083-44096.
15. Kassiri Z., Oudit G.Y., Sanchez O., Dawood F., Mohammed F.F., Nuttall R.K., et al. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circulation Research 2005, 97:380-390.
16. Fedak P.W., Smookler D.S., Kassiri Z., Ohno N., Leco K.J., Verma S., et al. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 2004, 110:2401-2409.
17. Qi J.H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Medicine 2003, 9:407-415.
18. Saunders W.B., Bohnsack B.L., Faske J.B., Anthis N.J., Bayless K.J., Hirschi K.K., et al. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. Journal of Cell Biology 2006, 175:179-191.
19. Kandalam V., Basu R., Abraham T., Wang X., Awad A., Wang W., et al. Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology 2010, 299:H1012-H1023.
20. Tian H., Cimini M., Fedak P.W., Altamentova S., Fazel S., Huang M.L., et al. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. Journal of Molecular and Cellular Cardiology 2007, 43:733-743.
21. Carnevale D., Cifelli G., Mascio G., Madonna M., Sbroggio M., Perrino C., et al. Placental growth factor regulates cardiac inflammation through the tissue inhibitor of metalloproteinases-3/tumor necrosis factor-alpha-converting enzyme axis: crucial role for adaptive cardiac remodeling during cardiac pressure overload. Circulation 2011, 124:1337-1350.
22. Fedak P.W., Altamentova S.M., Weisel R.D., Nili N., Ohno N., Verma S., et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. American Journal of Physiology. Heart and Circulatory Physiology 2003, 284:H626-H634.
23. Fiorentino L., Cavalera M., Mavilio M., Conserva F., Menghini R., Gesualdo L., et al. Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs. Acta Diabetologica 2013, 50:965-969.
24. Stohr R., Cavalera M., Menini S., Mavilio M., Casagrande V., Rossi C., et al. Loss of TIMP3 exacerbates atherosclerosis in ApoE null mice. Atherosclerosis 2014, 235:438-443.
25. Tarnavski O., McMullen J.R., Schinke M., Nie Q., Kong S., Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiological Genomics 2004, 16:349-360.
26. Marino A., Menghini R., Fabrizi M., Casagrande V., Mavilio M., Stoehr R., et al. ITCH deficiency protects from diet-induced obesity. Diabetes 2014, 63:550-561.
27. Attane C., Foussal C., Le Gonidec S., Benani A., Daviaud D., Wanecq E., et al. Apelin treatment increases complete fatty acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice. Diabetes 2012, 61:310-320.
28. Saeed A.I., Bhagabati N.K., Braisted J.C., Liang W., Sharov V., Howe E.A., et al. TM4 microarray software suite. Methods in Enzymology 2006, 411:134-193.
29. Braun A., Trigatti B.L., Post M.J., Sato K., Simons M., Edelberg J.M., et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circulation Research 2002, 90:270-276.
30. Martin K.R. The bioactive agent ergothioneine, a key component of dietary mushrooms, inhibits monocyte binding to endothelial cells characteristic of early cardiovascular disease. Journal of Medicinal Food 2010, 13:1340-1346.
31. Nagarajan S., Burris R.L., Stewart B.W., Wilkerson J.E., Badger T.M. Dietary soy protein isolate ameliorates atherosclerotic lesions in apolipoprotein E-deficient mice potentially by inhibiting monocyte chemoattractant protein-1 expression. Journal of Nutrition 2008, 138:332-337.
32. Ko Y.E., Lee I.H., So H.M., Kim H.W., Kim Y.H. Mechanism of glutathione depletion during simulated ischemia-reperfusion of H9c2 cardiac myocytes. Free Radical Research 2011, 45:1074-1082.
33. Valbuena-Diez A.C., Blanco F.J., Oujo B., Langa C., Gonzalez-Nunez M., Llano E., et al. Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation 2012, 126:2612-2624.
34. Barth J.L., Yu Y., Song W., Lu K., Dashti A., Huang Y., et al. Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes. Diabetologia 2007, 50:2200-2208.
35. Hayter H.L., Pettus B.J., Ito F., Obeid L.M., Hannun Y.A. TNFalpha-induced glutathione depletion lies downstream of cPLA(2) in L929 cells. FEBS Letters 2001, 507:151-156.
36. Egom E.E., Mamas M.A., Chacko S., Stringer S.E., Charlton-Menys V., El-Omar M., et al. Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. Frontiers in Physiology 2013, 4:130.
37. Knapp M., Zendzian-Piotrowska M., Blachnio-Zabielska A., Zabielski P., Kurek K., Gorski J. Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat. Basic Research in Cardiology 2012, 107:294.
38. Cavalli A.M.L.J., Gellings N.M., Castro E., Page T.M., Klepper R.E., Palade P.T., et al. The role of TNFα and sphingolipid signaling in cardiac hypoxia: evidence that cardiomyocytes release TNFα and sphingosine. Basic and Applied Myology 2002, 12:167-175.
39. Cordis G.A., Yoshida T., Das D.K. HPTLC analysis of sphingomylein, ceramide and sphingosine in ischemic/reperfused rat heart. Journal of Pharmaceutical and Biomedical Analysis 1998, 16:1189-1193.
40. Bai Y., Wang J., Shan H., Lu Y., Zhang Y., Luo X., et al. Sphingolipid metabolite ceramide causes metabolic perturbation contributing to HERG K+ channel dysfunction. Cellular Physiology and Biochemistry 2007, 20:429-440.
41. Dobrzyn P., Sampath H., Dobrzyn A., Miyazaki M., Ntambi J.M. Loss of stearoyl-CoA desaturase 1 inhibits fatty acid oxidation and increases glucose utilization in the heart. American Journal of Physiology. Endocrinology and Metabolism 2008, 294:E357-E364.
42. Campbell F.M., Kozak R., Wagner A., Altarejos J.Y., Dyck J.R., Belke D.D., et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. Journal of Biological Chemistry 2002, 277:4098-4103.
43. Kolwicz S.C., Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovascular Research 2011, 90:194-201.
44. Sambandam N., Morabito D., Wagg C., Finck B.N., Kelly D.P., Lopaschuk G.D. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. American Journal of Physiology. Heart and Circulatory Physiology 2006, 290:H87-H95.
45. Yue T.L., Bao W., Jucker B.M., Gu J.L., Romanic A.M., Brown P.J., et al. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 2003, 108:2393-2399.
46. Lou P.H., Zhang L., Lucchinetti E., Heck M., Affolter A., Gandhi M., et al. Infarct-remodelled hearts with limited oxidative capacity boost fatty acid oxidation after conditioning against ischaemia/reperfusion injury. Cardiovascular Research 2013, 97:251-261.
47. Sena S., Hu P., Zhang D., Wang X., Wayment B., Olsen C., et al. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. Journal of Molecular and Cellular Cardiology 2009, 46:910-918.
48. Ferdous A., Battiprolu P.K., Ni Y.G., Rothermel B.A., Hill J.A. FoxO, autophagy, and cardiac remodeling. Journal of Cardiovascular Translational Research 2010, 3:355-364.
49. Castan-Laurell I., Dray C., Knauf C., Kunduzova O., Valet P. Apelin, a promising target for type 2 diabetes treatment?. Trends in Endocrinology & Metabolism 2012, 23:234-241.
50. Chandrasekaran B., Kalra P.R., Donovan J., Hooper J., Clague J.R., McDonagh T.A. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. Journal of Cardiac Failure 2010, 16:556-561.
51. Wang W., McKinnie S.M., Patel V.B., Haddad G., Wang Z., Zhabyeyev P., et al. Loss of apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic apelin analogues. Journal of the American Heart Association 2013, 2:e000249.
52. Scimia M.C., Hurtado C., Ray S., Metzler S., Wei K., Wang J., et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 2012, 488:394-398.
53. Tempel D., de Boer M., van Deel E.D., Haasdijk R.A., Duncker D.J., Cheng C., et al. Apelin enhances cardiac neovascularization after myocardial infarction by recruiting aplnr+ circulating cells. Circulation Research 2012, 111:585-598.
54. Li L., Zeng H., Chen J.X. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology 2012, 303:H605-H618.
55. Azizi Y., Faghihi M., Imani A., Roghani M., Nazari A. Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides 2013, 46:76-82.
56. Foussal C., Lairez O., Calise D., Pathak A., Guilbeau-Frugier C., Valet P., et al. Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Letters 2010, 584:2363-2370.
57. Pisarenko O.I., Lankin V.Z., Konovalova G.G., Serebryakova L.I., Shulzhenko V.S., Timoshin A.A., et al. Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion. Molecular and Cellular Biochemistry 2014, 391:241-250.
58. Pchejetski D., Foussal C., Alfarano C., Lairez O., Calise D., Guilbeau-Frugier C., et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. European Heart Journal 2012, 33:2360-2369.
59. Kallergis E.M., Manios E.G., Kanoupakis E.M., Mavrakis H.E., Goudis C.A., Maliaraki N.E., et al. Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation. American Journal of Cardiology 2010, 105:90-94.
60. Ellinor P.T., Low A.F., Macrae C.A. Reduced apelin levels in lone atrial fibrillation. European Heart Journal 2006, 27:222-226.
61. Targher G., Valbusa F., Bonapace S., Bertolini L., Zenari L., Pichiri I., et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutrition, Metabolism & Cardiovascular Diseases 2014, 24:663-669.
62. Murthy A., Shao Y.W., Defamie V., Wedeles C., Smookler D., Khokha R. Stromal TIMP3 regulates liver lymphocyte populations and provides protection against Th1 T cell-driven autoimmune hepatitis. Journal of Immunology 2012, 188:2876-2883.
63. Backhed F., Manchester J.K., Semenkovich C.F., Gordon J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:979-984.